New paper from Japan [1].
The antiandrogen flutamide was approved by the FDA for PCa thirty years ago. Bicalutamide had been approved by the FDA a few years earlier.
The paper presents an anecdotal case of a man "in whom flutamide controlled disease progression for 10 years" "after bicalutamide failure".
-Patrick
[1] ncbi.nlm.nih.gov/pubmed/318...
Nagoya J Med Sci. 2019 Nov;81(4):707-710. doi: 10.18999/nagjms.81.4.707.
A case of advanced prostate cancer controlled for the long term by flutamide after bicalutamide failure.
Muramatsu T1, Funahashi Y1, Yamamoto A1, Sassa N1, Matsukawa Y1, Gotoh M1.
Author information
1
Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Abstract
Currently, the early introduction of new antiandrogens is popular for castration-resistant prostate cancer (CRPC). However, adverse events can be severe and their costs are high. Here, we present a patient with CRPC in whom flutamide controlled disease progression for 10 years. This case report shows that conventional alternative antiandrogens are cost effective and are still an important option for the treatment for CRPC.
KEYWORDS:
bicalutamide; flutamide; long-term; prostate cancer
PMID: 31849389 PMCID: PMC6892669 DOI: 10.18999/nagjms.81.4.707
